GM1对帕金森病治疗作用的实验研究

研究单唾液酸四己糖神经节苷脂(GM1)对帕金森病(PD)的治疗作用。运用选择性偏侧(右侧)PD大鼠模型，观测正常对照组、PD组(造模后14d)、PD生理盐水(NS)治疗组和GM1治疗组(10mg／kgIPqd、连续14d)，阿朴吗啡(APO)诱发的旋转行为改变和纹状体线粒体钙(MCa)、钙调素(CaM)含量改变。PD组表现明显的APO诱发的旋转行为(≥6r／min)，黑质损伤侧(右侧)纹状体MCa、CaM含量与正常对照组比较显著性升高(P<0．01)；GM1治疗组APO诱发的旋转行为明显好转，黑质损伤侧纹状体MCa、CaM含量与PD组比较无显著差异性(P>0．05)。GM1能改善实验性PD的部分行为、生化改变，对PD具有治疗作用。

An Experimental Study on the Treatment of Pakinson's Disease with GM1

The treatment of Parkinson's disease (PD) with GM1 was studied. By using selective lateral (right) rat PD model, the changes in rotational behavior induced by apomorphine (APO), striatum mitochondria calcium (MCa), Calmodulin (CaM) contents in the control group, PD group, normal sodium group (NS) and GM1-treated PD group (10 mg/kg IP, once daily for 14 days) were observed. In PD group (14 days) obvious APO-induced rotational behaviors (≥6 r/min) was observed. As compared with control group, striatum Mca and CaM contents on the injured side (right) of substantia nigra were increased significantly (P＜0. 01).The APO-induced rotational behaviors and striatum Mca and CaM contents in the GM1-treated PD group were improved significantly (P＜0. 01), but there was no significant difference in MCa and CaM contents in the injured side of substantia nigra between the NS-treated PD group and PD groups (P＞0. 05). GM1 could partially improve the behavioral and biochemical changes of experimental PD and had therapeutic effects on PD.